NCT04573244 (HEMO-AI) is a clinical trial in Hemoglobin; Deficiency, sponsored by MYOR Ltd..

Who is sponsoring NCT04573244?

NCT04573244 is sponsored by MYOR Ltd..

What condition does NCT04573244 study?

NCT04573244 studies Hemoglobin; Deficiency.

Is NCT04573244 still recruiting?

NCT04573244 is currently completed. Last updated 23 August 2024.

Last reviewed 2024-08-23 · How we verify

NCT04573244: HEMO-AI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hemoglobin Easy Measurement With Optical Artificial Intelligence

Completed Last updated 23 August 2024

What this trial tests

trial in Hemoglobin; Deficiency in 823 participants. Completed in 31 August 2023.

Timeline

2 December 2020

Primary endpoint
31 August 2023

31 August 2023

Quick facts

Lead sponsor	MYOR Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	823
Start date	2 December 2020
Primary completion	31 August 2023
Estimated completion	31 August 2023
Sites	1 location across Israel

Conditions studied

Hemoglobin; Deficiency — all drugs for Hemoglobin; Deficiency →

Sponsor

MYOR Ltd.

Who can join

Adults 6 Months to 18, any sex, with Hemoglobin; Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Blood hemoglobin levels are an extremely important measure for a large swath of medical procedures as they reflect the oxygen-carrying capacity of human blood. The gold standard measure for blood hemoglobin levels involve a venous blood draw followed by a laboratory-based complete blood count (CBC), a process which is both painful and time consuming. To date, various methodologies have been tested to either expediate the process or provide a non-invasive alternative. There remains a need to provide a quick, pain-free/non-invasive and accurate modality to measure blood hemoglobin levels. The objective of this study is to determine whether computer vision technologies can be applied to fingernail images captured via a smartphone camera to quantify blood hemoglobin levels.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Artificial intelligence-enabled non-invasive ubiquitous anemia screening: The HEMO-AI pilot study on pediatric population.
Gordon D, Hoffman J, Gamrasni K, Barlev Y, et al · · 2024 · cited 1× · PMID 39640961 · DOI 10.1177/20552076241297057

Verify or expand the search:

Other MYOR Ltd. trials

Trials by the same sponsor.

NCT04325451 — Comprehending Atopic Risk Elements · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04573244 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MYOR Ltd.
Last refreshed: 23 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04573244.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing